Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 22822065)

1.

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Martin B, Chadwick W, Cong WN, Pantaleo N, Daimon CM, Golden EJ, Becker KG, Wood WH 3rd, Carlson OD, Egan JM, Maudsley S.

J Biol Chem. 2012 Sep 14;287(38):31766-82. doi: 10.1074/jbc.M112.387316. Epub 2012 Jul 20.

2.

Altered hypothalamic protein expression in a rat model of Huntington's disease.

Cong WN, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, Canneva F, von Hörsten S, Martin B.

PLoS One. 2012;7(10):e47240. doi: 10.1371/journal.pone.0047240. Epub 2012 Oct 18. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/677c26e3-ce52-4837-853a-63c4ed7d72c0.

3.

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.

Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM.

Diabetes. 2009 Feb;58(2):318-28. doi: 10.2337/db08-0799. Epub 2008 Nov 4.

4.

Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.

Klevytska AM, Tebbenkamp AT, Savonenko AV, Borchelt DR.

J Neuropathol Exp Neurol. 2010 Apr;69(4):396-404. doi: 10.1097/NEN.0b013e3181d6c436.

PMID:
20448484
5.

Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ.

Cabou C, Vachoux C, Campistron G, Drucker DJ, Burcelin R.

Diabetes. 2011 Sep;60(9):2245-56. doi: 10.2337/db11-0464. Epub 2011 Aug 1.

6.

Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.

Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, Neslon C, Chan N, Eaton M, Fromholt D, Ross CA, Borchelt DR.

Exp Neurol. 2004 May;187(1):137-49.

PMID:
15081595
7.

Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.

Mughal MR, Baharani A, Chigurupati S, Son TG, Chen E, Yang P, Okun E, Arumugam T, Chan SL, Mattson MP.

Hum Mol Genet. 2011 Feb 15;20(4):659-69. doi: 10.1093/hmg/ddq512. Epub 2010 Nov 24. Erratum in: Hum Mol Genet. 2011 May 15;20(10):2078.

8.

Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.

Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK.

Neurobiol Dis. 2002 Dec;11(3):410-24.

PMID:
12586550
9.

Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.

Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W.

Neurobiol Dis. 2008 Jun;30(3):293-302. doi: 10.1016/j.nbd.2008.01.014. Epub 2008 Mar 10.

10.

Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.

Cheng Y, Peng Q, Hou Z, Aggarwal M, Zhang J, Mori S, Ross CA, Duan W.

Neuroimage. 2011 Jun 1;56(3):1027-34. doi: 10.1016/j.neuroimage.2011.02.022. Epub 2011 Feb 12.

11.

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.

Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE.

Am J Physiol Endocrinol Metab. 2012 Feb 1;302(3):E334-43. doi: 10.1152/ajpendo.00409.2011. Epub 2011 Nov 15.

12.

Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.

Cong WN, Chadwick W, Wang R, Daimon CM, Cai H, Amma J, Wood WH 3rd, Becker KG, Martin B, Maudsley S.

J Biol Chem. 2015 Jan 30;290(5):2728-43. doi: 10.1074/jbc.M114.588608. Epub 2014 Dec 11.

PMID:
25505248
13.

Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.

Schilling G, Klevytska A, Tebbenkamp AT, Juenemann K, Cooper J, Gonzales V, Slunt H, Poirer M, Ross CA, Borchelt DR.

J Neuropathol Exp Neurol. 2007 Apr;66(4):313-20.

PMID:
17413322
14.

Huntington's disease does not appear to increase the risk of diabetes mellitus.

Boesgaard TW, Nielsen TT, Josefsen K, Hansen T, Jørgensen T, Pedersen O, Nørremølle A, Nielsen JE, Hasholt L.

J Neuroendocrinol. 2009 Sep;21(9):770-6. doi: 10.1111/j.1365-2826.2009.01898.x. Epub 2009 Jul 7.

PMID:
19602103
15.

Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.

Chiu CT, Liu G, Leeds P, Chuang DM.

Neuropsychopharmacology. 2011 Nov;36(12):2406-21. doi: 10.1038/npp.2011.128. Epub 2011 Jul 27.

16.

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity.

Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Pénicaud L, Drucker DJ, Magnan C, Burcelin R.

Diabetes. 2008 Oct;57(10):2577-87. doi: 10.2337/db08-0121. Epub 2008 Jul 15.

17.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1939-51.

18.

Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.

Luthi-Carter R, Strand AD, Hanson SA, Kooperberg C, Schilling G, La Spada AR, Merry DE, Young AB, Ross CA, Borchelt DR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1927-37.

19.

Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.

Kim PH, Lee M, Kim SW.

J Control Release. 2012 Aug 20;162(1):9-18. doi: 10.1016/j.jconrel.2012.06.010. Epub 2012 Jun 15.

20.

Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk